2. Search Result
Search Result
Results for "

plaque psoriasis

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

11

Inhibitory Antibodies

8

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117287
    Deucravacitinib
    30+ Cited Publications

    BMS-986165

    		 JAK STAT Interleukin Related IFNAR Inflammation/Immunology
    Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .
    Deucravacitinib
  • HY-108847
    Etanercept
    Maximum Cited Publications
    15 Publications Verification

    		 TNF Receptor Bacterial Inflammation/Immunology Cancer
    Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .
    Etanercept
  • HY-P9927
    Secukinumab
    5+ Cited Publications

    AIN457

    		 Interleukin Related Inflammation/Immunology Cancer
    Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .
    Secukinumab
  • HY-P9924
    Ixekizumab

    LY2439821

    		 Interleukin Related Inflammation/Immunology
    Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .
    Ixekizumab
  • HY-177129
    Simepdekinra

    LY4100511; DC-853

    		 Interleukin Related Inflammation/Immunology
    Simepdekinra (LY4100511; DC-853) is an IL-17A antagonist. Simepdekinra can be used in the research of moderate to severe plaque-type psoriasis .
    Simepdekinra
  • HY-15388
    Tazarotene
    2 Publications Verification

    AGN 190168

    		 RAR/RXR Autophagy Inflammation/Immunology Cancer
    Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris. Tazarotene is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Tazarotene
  • HY-P9925
    Brodalumab
    4 Publications Verification

    AMG 827; KHK4827

    		 Interleukin Related Inflammation/Immunology
    Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis .
    Brodalumab
  • HY-16755
    Solcitinib
    3 Publications Verification

    GSK-2586184; GLPG-0778

    		 JAK Inflammation/Immunology
    Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.
    Solcitinib
  • HY-P99256
    Tildrakizumab

    SCH 900222; MK 3222; Anti-Human IL23 Recombinant Antibody

    		 Interleukin Related Inflammation/Immunology Cancer
    Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
    Tildrakizumab
  • HY-P99754
    Netakimab

    BCD-085

    		 Interleukin Related Infection Inflammation/Immunology
    Netakimab (BCD-085) is a humanized IgG1κ monoclonal anti-IL-17 antibody that binds to and blocks IL-17 and IL-17A activity, including reduction of downstream IL-6 production. Netakimab can be used for the research of moderate-to-severe plaque psoriasis, ankylosing spondylitis, and COVID-19 with cytokine release syndrome . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Netakimab
  • HY-120384
    AZD-0284
    3 Publications Verification

    		 ROR Inflammation/Immunology
    AZD-0284 is a selective inverse agonist of the nuclear receptor RORγ. AZD-0284 has the potential for plaque psoriasis vulgaris and respiratory tract disorders treatment .
    AZD-0284
  • HY-P9947
    Efalizumab
    1 Publications Verification

    		 Integrin Others
    Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research .
    Efalizumab
  • HY-153701S
    Envudeucitinibum

    Envudeucitinib; ESK-001

    		 JAK Interleukin Related IFNAR Isotope-Labeled Compounds Inflammation/Immunology
    Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases .
    Envudeucitinibum
  • HY-P99940
    Remtolumab

    ABT-122

    		 TNF Receptor Interleukin Related Inflammation/Immunology
    Remtolumab is a bispecific variable domain immunoglobulin molecule with human affinities for TNFα and IL-17 in the low pM range of Kd. Remtolumab can be used in research related to rheumatoid arthritis, psoriatic arthritis, and moderate-to-severe plaque psoriasis .
    Remtolumab
  • HY-P99335
    Vunakizumab

    Anti-Human IL17A Recombinant Antibody; SHR-1314

    		 Interleukin Related Inflammation/Immunology
    Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody and an Interleukin-17A (IL-17A) inhibitor. Vunakizumab binds to IL-17A to inhibit downstream cytokines and block inflammatory signaling. Vunakizumab can be used for the research of chronic plaque psoriasis and ankylosing spondylitis .
    Vunakizumab
  • HY-109105
    Tepilamide fumarate

    XP-23829; PPC-06

    		 Drug Derivative Inflammation/Immunology
    Tepilamide fumarate (XP-23829; PPC-06) is an oral fumaric acid ester, acts as a proagent ofMonomethyl fumarate (HY-103252), and is used in the research of moderate to severe chronic plaque psoriasis. Tepilamide fumarate can enhance the effectiveness of oncolytic viruses .
    Tepilamide fumarate
  • HY-144683A
    PF-07038124 hydrochloride

    		Phosphodiesterase (PDE) Inflammation/Immunology
    PF-07038124 hydrochloride is a PDE4 inhibitor with an IC50 of 0.5 nM for PDE4B2. PF-07038124 hydrochloride shows inhibitory activities against IL-13, IL4, and IFNγ (IC50=125, 4.1, 1.06 nM, respectively). PF-07038124 hydrochloride can be used for research of atopic dermatitis and plaque psoriasis .
    PF-07038124 hydrochloride
  • HY-151365
    IRAK4-IN-22

    		IRAK Inflammation/Immunology
    IRAK4-IN-22 (compound 18) is an orally active, potent and selective IRAK4 inhibitor with IC50 values of 3 and 17 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC50=0.10 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .
    IRAK4-IN-22
  • HY-151363
    IRAK4-IN-21

    		IRAK Inflammation/Immunology
    IRAK4-IN-21 (compound 17) is an orally active, potent and selective IRAK4 inhibitor with IC50 values of 5 and 56 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC50=0.17 μM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .
    IRAK4-IN-21
  • HY-177617
    Bazlitoran

    IMO-8400

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Bazlitoran (IMO-8400) is an oligonucleotide-based TLR7/8/9 antagonist. Bazlitoran blocks the activation of Toll-like receptors 7, 8, and 9. Bazlitoran inhibits cytokine responses mediated by Toll-like receptors 7, 8, and 9. Bazlitoran is associated with injection site reactions. Bazlitoran improves moderate-to-severe plaque psoriasis .
    Bazlitoran
  • HY-144683
    PF-07038124

    		Phosphodiesterase (PDE) Inflammation/Immunology
    PF-07038124 is a PDE4 inhibitor with an IC50 of 0.5 nM for PDE4B2. PF-07038124 shows inhibitory activities against IL-13, IL4, and IFNγ (IC50=125, 4.1, 1.06 nM, respectively). PF-07038124 can be used for research of atopic dermatitis and plaque psoriasis .
    PF-07038124
  • HY-177617A
    Bazlitoran sodium

    IMO-8400 sodium

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Bazlitoran sodium (IMO-8400 sodium) is an oligonucleotide-based TLR7/8/9 antagonist. Bazlitoran sodium blocks the activation of Toll-like receptors 7, 8, and 9. Bazlitoran sodium inhibits cytokine responses mediated by Toll-like receptors 7, 8, and 9. Bazlitoran sodium is associated with injection site reactions. Bazlitoran sodium improves moderate-to-severe plaque psoriasis .
    Bazlitoran sodium
  • HY-160144S2
    (rac)-Lomedeucitinib

    (rac)-BMS-986322

    		 Drug Isomer Others
    (rac)-Lomedeucitinib ((rac)-BMS-986322) is the racemate of Lomedeucitinib. Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor. Lomedeucitinib has anti-inflammatory activity and significant inhibitory effect on IFNα (IC50=0.047 μM) production downstream of IL-12/TYK2. Lomedeucitinib is indicated for the study of plaque psoriasis and pruritus .
    (rac)-Lomedeucitinib
  • HY-158159
    IL17A-IN-1

    		Interleukin Related Inflammation/Immunology Cancer
    IL17A-IN-1 (compound 72) is an orally active Interleukin 17A inhibitor. IL17A-IN-1 can be used in the study of inflammatory and autoimmune diseases (plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, etc.), as well as cancer .
    IL17A-IN-1
  • HY-117287A
    Deucravacitinib (hydrochloride)

    BMS-986165 (hydrochloride)

    		 IFNAR STAT Interleukin Related JAK Inflammation/Immunology
    Deucravacitinib (BMS-986165) hydrochloride is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib hydrochloride blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib hydrochloride can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .
    Deucravacitinib (hydrochloride)
  • HY-15388S
    Tazarotene-d8

    AGN 190168-d8

    		 Isotope-Labeled Compounds RAR/RXR Autophagy Inflammation/Immunology Cancer
    Tazarotene-d8 is the deuterium labeled Tazarotene. Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris .
    Tazarotene-d8
  • HY-15388R
    Tazarotene (Standard)

    AGN 190168 (Standard)

    		 Reference Standards RAR/RXR Autophagy Inflammation/Immunology Cancer
    Tazarotene (Standard) is the analytical standard of Tazarotene. This product is intended for research and analytical applications. Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris. Tazarotene is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Tazarotene (Standard)
  • HY-15388S2
    Tazarotene-13C6

    AGN 190168-13C6

    		 Isotope-Labeled Compounds RAR/RXR Autophagy Inflammation/Immunology Cancer
    Tazarotene- 13C6 (AGN 190168- 13C6) is 13C labeled Tazarotene. Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris. Tazarotene is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Tazarotene-13C6
  • HY-15388S1
    Tazarotene-13C2,d2

    AGN 190168-13C2,d2

    		 Isotope-Labeled Compounds Inflammation/Immunology Cancer
    Tazarotene-13C2,d2 (AGN 190168-13C2,d2) is the 13C and deuterium labeled isotope of Tazarotene (HY-15388). Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris. Tazarotene is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups .
    Tazarotene-13C2,d2
  • HY-32347
    Tisocalcitate

    		VD/VDR Inflammation/Immunology
    Tisocalcitate is a Vitamin D analogue, can be used for plaque type psoriasis research .
    Tisocalcitate
  • HY-14869
    Revamilast

    GRC 4039

    		 Phosphodiesterase (PDE) TNF Receptor Inflammation/Immunology
    Revamilast (GRC 4039) is an orally active phosphodiesterase-4 (PDE4) inhibitor with an IC50 of 3 nM. Revamilast inhibits the production of TNF-α. It can be used for research on rheumatoid arthritis, plaque psoriasis, asthma, and other inflammatory diseases .
    Revamilast
  • HY-15388S3
    Tazarotene-d6

    AGN 190168-d6

    		 Isotope-Labeled Compounds Inflammation/Immunology Cancer
    Tazarotene-d6 (AGN 190168-d6) is deuterium labeled Tazarotene. Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris. Tazarotene is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Tazarotene-d6
  • HY-166594S
    Deucravacitinib-13C,d3

    		Isotope-Labeled Compounds IFNAR Interleukin Related JAK Inflammation/Immunology
    Deucravacitinib- 13C,d3 is the 13C- and deuterium labeled Deucravacitinib. Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis .
    Deucravacitinib-13C,d3
  • HY-P992053
    Anti-CD11a Antibody (MHM24)

    		Integrin Inflammation/Immunology
    Anti-CD11a Antibody (MHM24) is a monoclonal antibody targeting murine CD11a. Anti-CD11a Antibody (MHM24) binds to high-affinity (open) and low-affinity (closed) conformations of the αL subunit of LFA-1, and functionally blocks LFA-1-mediated interactions. Anti-CD11a Antibody (MHM24) blocks ICAM-1 binding to LFA-1-expressing cells. Anti-CD11a Antibody (MHM24) inhibits adhesion of high-affinity LFA-1-expressing cells to keratinocytes. Anti-CD11a Antibody (MHM24) inhibits PHA-induced lymphocyte proliferation. Anti-CD11a Antibody (MHM24) can be used for the research of inflammatory and autoimmune diseases. Recommend Isotype Controls: mouse IgG1 kappa, Isotype Control (HY-P99977) .
    Anti-CD11a Antibody (MHM24)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: